Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study

J. Wolf; T. Overbeck; J. -Y. Han; M. Hochmair; F. De Marinis; K. Ohashi; E. F. Smit; D. Power; E. B. Garon; H. J. M. Groen; D. S. W. Tan; M. Waldron-Lynch; S. Le Mouhaer; N. Nwana; M. Giovannini; R. S. Heist

Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study

J. Wolf, T. Overbeck, J. -Y. Han, M. Hochmair, F. De Marinis, K. Ohashi, E. F. Smit, D. Power, E. B. Garon, H. J. M. Groen, D. S. W. Tan, M. Waldron-Lynch, S. Le Mouhaer, N. Nwana, M. Giovannini, R. S. Heist

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	150-151
Number of pages	2
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - Oct-2020

Cite this

Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., & Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncology Research and Treatment, 43(SUPPL 4), 150-151.

Wolf, J. ; Overbeck, T. ; Han, J. -Y. ; Hochmair, M. ; De Marinis, F. ; Ohashi, K. ; Smit, E. F. ; Power, D. ; Garon, E. B. ; Groen, H. J. M. ; Tan, D. S. W. ; Waldron-Lynch, M. ; Le Mouhaer, S. ; Nwana, N. ; Giovannini, M. ; Heist, R. S. / Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC) : results from the phase 2 GEOMETRY mono-1 study. In: Oncology Research and Treatment. 2020 ; Vol. 43, No. SUPPL 4. pp. 150-151.

@article{431c1df110c14b15b0911324456a0abc,

title = "Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study",

author = "J. Wolf and T. Overbeck and Han, {J. -Y.} and M. Hochmair and {De Marinis}, F. and K. Ohashi and Smit, {E. F.} and D. Power and Garon, {E. B.} and Groen, {H. J. M.} and Tan, {D. S. W.} and M. Waldron-Lynch and {Le Mouhaer}, S. and N. Nwana and M. Giovannini and Heist, {R. S.}",

year = "2020",

month = oct,

language = "English",

volume = "43",

pages = "150--151",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "KARGER",

number = "SUPPL 4",

}

Wolf, J, Overbeck, T, Han, J-Y, Hochmair, M, De Marinis, F, Ohashi, K, Smit, EF, Power, D, Garon, EB, Groen, HJM, Tan, DSW, Waldron-Lynch, M, Le Mouhaer, S, Nwana, N, Giovannini, M & Heist, RS 2020, 'Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study', Oncology Research and Treatment, vol. 43, no. SUPPL 4, pp. 150-151.

Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC) : results from the phase 2 GEOMETRY mono-1 study. / Wolf, J.; Overbeck, T.; Han, J. -Y.; Hochmair, M.; De Marinis, F.; Ohashi, K.; Smit, E. F.; Power, D.; Garon, E. B.; Groen, H. J. M.; Tan, D. S. W.; Waldron-Lynch, M.; Le Mouhaer, S.; Nwana, N.; Giovannini, M.; Heist, R. S.

In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 10.2020, p. 150-151.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC)

T2 - results from the phase 2 GEOMETRY mono-1 study

AU - Wolf, J.

AU - Overbeck, T.

AU - Han, J. -Y.

AU - Hochmair, M.

AU - De Marinis, F.

AU - Ohashi, K.

AU - Smit, E. F.

AU - Power, D.

AU - Garon, E. B.

AU - Groen, H. J. M.

AU - Tan, D. S. W.

AU - Waldron-Lynch, M.

AU - Le Mouhaer, S.

AU - Nwana, N.

AU - Giovannini, M.

AU - Heist, R. S.

PY - 2020/10

Y1 - 2020/10

M3 - Meeting Abstract

VL - 43

SP - 150

EP - 151

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - SUPPL 4

ER -